Two types of colistin heteroresistance in Acinetobacter baumannii isolates

References

• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271–1281.
   PubMed Web of Science ®Google Scholar
• Ko KS, Choi Y, Lee JY. Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii. Precis Future Med. 2017;1:159–167.
   Web of Science ®Google Scholar
• WHO publishes list of bacteria for which new antibiotics are urgently needed 2017. Available from: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibioticsneeded/en/
   Google Scholar
• Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557–596.
   PubMed Web of Science ®Google Scholar
• Storm DR, Rosentha KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723–763.
   PubMed Web of Science ®Google Scholar
• Velkov T, Thompson PE, Nation RL, et al. Structure-activity relationships of polymyxin antibiotics. J Med Chem. 2010;53:1898–1916.
   PubMed Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53:3628–3634.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Mansell A, et al. Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Antimicrob Agents Chemother. 2010;81:684–689.
   Google Scholar
• Park YK, Choi JY, Shin D, et al. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 2011;37:525–530.
   PubMed Web of Science ®Google Scholar
• Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17:479–496.
   PubMed Web of Science ®Google Scholar
• El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28:191–207.
   PubMed Web of Science ®Google Scholar
• Charretier Y, Diene SM, Baud D, et al. Colistin heteroresistance and involvement of the PmrAB regulatory system in Acinetobacter baumannii. Antimicrob Agents Chemother. 2018;62:e00788–18.
   PubMed Web of Science ®Google Scholar
• Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother. 2008;52:351–352.
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:2946–2950.
   PubMed Web of Science ®Google Scholar
• Srinivas P, Hunt LN, Pouch SM, et al. Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates. Diagn Microbiol Infect Dis. 2018;91:194–198.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-ninth informational supplement. Document M100-S29. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• Gefen O, Chekol B, Strahilevitz J, et al. TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay. Sci Rep. 2017;7:41284.
   PubMed Web of Science ®Google Scholar
• Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007;51:3413–3415.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Ko KS. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother. 2014;69:275–277.
   PubMed Web of Science ®Google Scholar
• Javan AO, Sokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801–810.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Lewis JS, Weinstein MP et al. Clinical and laboratory standards institute (CLSI) and European committee on antimicrobial susceptibility testing (EUCAST) position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis 2020 (In press). doi:10.1093/cid/ciaa121.
   Web of Science ®Google Scholar
• Gai Z, Samodelov SL, Kullak-Ublick GA, et al. Molecular mechanisms of colistin-induced nephrotoxicity. Molecules. 2019;24:E653.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Dewan A. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17:15.
   PubMed Web of Science ®Google Scholar
• Arslan BY, Arslan F, Erkalp K, et al. Luteolin ameliorates colistin-induced nephrotoxicity in the rat models. Ren Fail. 2016;38:1735–1740.
   PubMed Web of Science ®Google Scholar
• Ko KS, Choi Y, Lee JY. Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii. Precis Future Med. 2017;1:159–167.
   Web of Science ®Google Scholar
• Lee JY, Choi MJ, Choi JH, et al. Preservation of acquired colistin resistance in gram-negative bacteria. Antimicrob Agents Chemother. 2016;60:609–612.
   PubMed Web of Science ®Google Scholar